Alivus Life

{
  "main_header": {
    "sid": 1003513,
    "name": "Alivus Life",
    "stock_name": "Alivus Life",
    "full_name": "Alivus Life Sciences Ltd",
    "name_url": "stocks-analysis/alivus-life",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,112.20",
    "chg": -3.9,
    "chgp": "-0.35%",
    "dir": -1,
    "prev_price": "1,116.10",
    "mcapval": "13,651.08 Cr",
    "mcap": "Small Cap",
    "scripcode": 543322,
    "symbol": "ALIVUS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE03Q201024",
    "curr_date": "Jun 25, 10:43 AM",
    "curr_time": "10:45 AM",
    "last_traded_at": "Jun 25, 10:43 AM IST",
    "bse_nse_vol": "16.04 k",
    "exc_status": "Active",
    "traded_date": "Jun 25, 2026",
    "traded_date_str": "2026 06 25",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/alivus-life-1003513-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Alivus Life Sciences Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-alivus-life-sciences-ltd-fallingrising-4069419",
        "imagepath": "",
        "date": "2026-06-24 01:43:37",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Performance and Market Positioning</strong></p>\n<p>Alivus Life Sciences has demonstrated impressive gains over multiple time horizons, significantly outperforming the broader market benchmarks. Over the past week, the stock surged by 7.29%, contrasting sharply with the Sensex’s decline of 0.79% during the same period. This positive trend extends over longer durations as well, with the stock delivering a 21.89% return year-to-date against the Sensex’s negative 10.58%. Even on a three-year basis, Alivus Life Sciences has nearly doubled in value, appreciating by 99.56%, far outpacing the Sensex’s 20.99% gain.</p>\n<p>On the day in question, the stock traded close to its 52-week high, just 2.77% shy of the peak price of ₹1,149. It also outperformed its sector by 2.53%, reflecting str..."
      },
      {
        "title": "Alivus Life Sciences Ltd Technical Momentum Shifts Signal Bullish Outlook",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alivus-life-sciences-ltd-technical-momentum-shifts-signal-bullish-outlook-4068213",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AlivusLifeScien_technicaldot_4068213.png",
        "date": "2026-06-23 08:07:42",
        "description": "Alivus Life Sciences Ltd has demonstrated a notable shift in price momentum, moving from a mildly bullish to a bullish technical trend, supported by a range of positive indicators including MACD, Bollinger Bands, and moving averages. This technical upgrade coincides with a recent Mojo Grade improvement from Hold to Buy, reflecting growing investor confidence in this small-cap pharmaceutical and biotechnology stock."
      },
      {
        "title": "Alivus Life Sciences Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/alivus-life-sciences-ltd-is-rated-hold-4063062",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AlivusLifeScien_mojoScore_4063062.png",
        "date": "2026-06-19 10:10:57",
        "description": "Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 26 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 June 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Alivus Life Sciences Ltd Valuation Shifts Signal Changing Market Sentiment",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alivus-life-sciences-ltd-valuation-shifts-signal-changing-market-sentiment-4040087",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AlivusLifeScien_valuationdot_4040087.png",
        "date": "2026-06-09 08:01:47",
        "description": "Alivus Life Sciences Ltd has recently undergone a notable shift in its valuation parameters, moving from a fair to an attractive rating. This change reflects improved price metrics relative to its historical averages and peer group, signalling a potential buying opportunity for investors in the Pharmaceuticals & Biotechnology sector despite a recent downgrade in its overall Mojo Grade to Hold."
      },
      {
        "title": "Alivus Life Sciences Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/alivus-life-sciences-ltd-is-rated-hold-4037165",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AlivusLifeScien_mojoScore_4037165.png",
        "date": "2026-06-08 10:10:40",
        "description": "Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 26 May 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Alivus Life Sciences Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/alivus-life-sciences-ltd-is-rated-hold-4037205",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AlivusLifeScien_mojoScore_4037205.png",
        "date": "2026-06-07 10:10:33",
        "description": "Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 26 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Alivus Life Sciences Ltd Gains 1.99%: 6 Key Factors Driving the Week’s Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alivus-life-sciences-ltd-gains-199-6-key-factors-driving-the-weeks-momentum-4022691",
        "imagepath": "",
        "date": "2026-05-30 11:04:20",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>25 May:</strong> Technical momentum shifts amid mixed signals</p>\n                    <p><strong>26 May:</strong> Intraday high surge of 7.06% to Rs.1,123</p>\n                    <p><strong>26 May:</strong> Bullish momentum upgrade with technical improvements</p>\n                    <p><strong>27 May:</strong> Downgrade to Hold amid mixed technical and valuation signals</p>\n                    <p><strong>27 May:</strong> Technical momentum shifts to mildly bullish</p>\n                    <p><strong>29 May:</strong> Week closes at Rs.1,056.55 (+1.99%) outperforming Sensex</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\">..."
      },
      {
        "title": "Alivus Life Sciences Downgraded to Hold Amid Mixed Technical and Valuation Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/alivus-life-sciences-downgraded-to-hold-amid-mixed-technical-and-valuation-signals-4016004",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AlivusLifeScien_mojoScore_4016004.png",
        "date": "2026-05-27 08:37:31",
        "description": "Alivus Life Sciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 26 May 2026. This adjustment reflects a nuanced reassessment across four critical parameters: quality, valuation, financial trend, and technicals. While the company continues to demonstrate solid fundamentals, evolving market dynamics and technical indicators have prompted a more cautious stance among analysts."
      },
      {
        "title": "Alivus Life Sciences Ltd Sees Shift in Technical Momentum Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alivus-life-sciences-ltd-sees-shift-in-technical-momentum-amid-mixed-indicator-signals-4015826",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AlivusLifeScien_technicaldot_4015826.png",
        "date": "2026-05-27 08:05:15",
        "description": "Alivus Life Sciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a nuanced market sentiment. While the stock price surged 3.86% on 27 May 2026 to ₹1,088.50, technical indicators present a mixed picture, signalling a transition from a bullish to a mildly bullish trend. This article analyses the recent technical parameter changes, key momentum indicators, and the stock’s relative performance against the broader market."
      }
    ],
    "total": 306,
    "sid": "1003513",
    "stock_news_url": "https://www.marketsmojo.com/news/alivus-life-sciences-1003513"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "23-Jun-2026",
      "details": "Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 - Intimation of Institutional Investor Meeting - Plant Visit",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "10-Jun-2026",
      "details": "Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 - Intimation of Analyst / Institutional Investor Meeting.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "04-Jun-2026",
      "details": "Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 - Intimation of Investors/Analyst Meeting",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Alivus Life Sciences Ltd has declared <strong>250%</strong> dividend, ex-date: 01 Sep 25",
          "dt": "2025-09-01",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Alivus Life Sciences Ltd falling/rising?

2026-06-24 01:43:37

Recent Price Performance and Market Positioning

Alivus Life Sciences has demonstrated impressive gains over multiple time horizons, significantly outperforming the broader market benchmarks. Over the past week, the stock surged by 7.29%, contrasting sharply with the Sensex’s decline of 0.79% during the same period. This positive trend extends over longer durations as well, with the stock delivering a 21.89% return year-to-date against the Sensex’s negative 10.58%. Even on a three-year basis, Alivus Life Sciences has nearly doubled in value, appreciating by 99.56%, far outpacing the Sensex’s 20.99% gain.

On the day in question, the stock traded close to its 52-week high, just 2.77% shy of the peak price of ₹1,149. It also outperformed its sector by 2.53%, reflecting str...

Read full news article

Alivus Life Sciences Ltd Technical Momentum Shifts Signal Bullish Outlook

2026-06-23 08:07:42

Alivus Life Sciences Ltd has demonstrated a notable shift in price momentum, moving from a mildly bullish to a bullish technical trend, supported by a range of positive indicators including MACD, Bollinger Bands, and moving averages. This technical upgrade coincides with a recent Mojo Grade improvement from Hold to Buy, reflecting growing investor confidence in this small-cap pharmaceutical and biotechnology stock.

Read full news article

Alivus Life Sciences Ltd is Rated Hold

2026-06-19 10:10:57

Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 26 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 June 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Alivus Life Sciences Ltd Valuation Shifts Signal Changing Market Sentiment

2026-06-09 08:01:47

Alivus Life Sciences Ltd has recently undergone a notable shift in its valuation parameters, moving from a fair to an attractive rating. This change reflects improved price metrics relative to its historical averages and peer group, signalling a potential buying opportunity for investors in the Pharmaceuticals & Biotechnology sector despite a recent downgrade in its overall Mojo Grade to Hold.

Read full news article

Alivus Life Sciences Ltd is Rated Hold

2026-06-08 10:10:40

Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 26 May 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Alivus Life Sciences Ltd is Rated Hold

2026-06-07 10:10:33

Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 26 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Alivus Life Sciences Ltd Gains 1.99%: 6 Key Factors Driving the Week’s Momentum

2026-05-30 11:04:20

Key Events This Week

25 May: Technical momentum shifts amid mixed signals

26 May: Intraday high surge of 7.06% to Rs.1,123

26 May: Bullish momentum upgrade with technical improvements

27 May: Downgrade to Hold amid mixed technical and valuation signals

27 May: Technical momentum shifts to mildly bullish

29 May: Week closes at Rs.1,056.55 (+1.99%) outperforming Sensex

...

Read full news article

Alivus Life Sciences Downgraded to Hold Amid Mixed Technical and Valuation Signals

2026-05-27 08:37:31

Alivus Life Sciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 26 May 2026. This adjustment reflects a nuanced reassessment across four critical parameters: quality, valuation, financial trend, and technicals. While the company continues to demonstrate solid fundamentals, evolving market dynamics and technical indicators have prompted a more cautious stance among analysts.

Read full news article

Alivus Life Sciences Ltd Sees Shift in Technical Momentum Amid Mixed Indicator Signals

2026-05-27 08:05:15

Alivus Life Sciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a nuanced market sentiment. While the stock price surged 3.86% on 27 May 2026 to ₹1,088.50, technical indicators present a mixed picture, signalling a transition from a bullish to a mildly bullish trend. This article analyses the recent technical parameter changes, key momentum indicators, and the stock’s relative performance against the broader market.

Read full news article

View All News